-
公开(公告)号：KR101351121B1
公开(公告)日：2014-01-14
申请号：KR1020110014438
申请日：2011-02-18
Applicant: 가톨릭대학교 산학협력단
Abstract: 본 발명은 IL-27을 유효성분으로 포함하는 면역거부질환의 예방 또는 치료용 조성물에 관한 것으로서, 보다 구체적으로 본 발명의 IL-27 단백질은 세포 또는 조직 이식 후 면역 거부 반응과 관련된 질환을 보이는 동물에게 투여하였을 때, 이식된 세포 또는 조직이 생착된 후 숙주에 대한 거부반응을 억제시킴으로써 면역거부질환을 완화시키는 효과를 갖는다. 따라서 상기와 같은 효과를 갖는 IL-27 단백질 및 IL-27 단백질을 암호화하는 핵산을 유효성분으로 포함하는 본 발명의 조성물은 면역 거부 반응 관련 질환의 예방 또는 치료에 유용하게 사용될 수 있는 특징이 있다.
-
公开(公告)号：KR1020130139512A
公开(公告)日：2013-12-23
申请号：KR1020120063017
申请日：2012-06-13
Applicant: 가톨릭대학교 산학협력단
IPC: A61K48/00 , A61K31/4164 , A61K31/495
CPC classification number: A61K48/005 , A61K31/4164 , A61K31/495 , A61K48/0058 , A61K2121/00
Abstract: The present invention relates to a composition for antiaging which includes a MDM2 inhibitor as an active ingredient and, more specifically, to a composition for preventing or treating aging or aging related diseases which includes a mouse double minute 2 (MDM2) inhibitor as an active ingredient. The MDM2 inhibitor according to the present invention has excellent effects of producing inflammatory cytokine and suppressing cytotoxic Th17 cells which secret the same and enhances activation of immune regulatory T cells (Treg) which suppresses immunocytes which are abnormally activated and controls inflammation reaction. In addition, the MDM2 inhibitor has activities of incresing expression of SOCS3 which can suppress activities of STAT3 and can be effectively used for manufacturing medicines which can suppress aging with various immune responses by having excellent antiaging effects specially when elders are treated with the MDM2 inhibitor.
Abstract translation: 本发明涉及一种抗衰老组合物，其包含MDM2抑制剂作为活性成分，更具体地，涉及用于预防或治疗老化或老化相关疾病的组合物，其包括小鼠双分钟2（MDM2）抑制剂作为活性成分 。 根据本发明的MDM2抑制剂具有产生炎性细胞因子和抑制细胞毒性Th17细胞的优良效果，其能够保密并增强免疫调节性T细胞（Treg）的活化，其抑制异常激活的免疫细胞并控制炎症反应。 此外，MDM2抑制剂具有可抑制STAT3活性的SOCS3表达的活性，并且可以有效地用于制造能够通过具有优异的抗衰老作用而抑制老化的药物，特别是当用MDM2抑制剂治疗老年人时。
-
公开(公告)号：KR101317492B1
公开(公告)日：2013-10-15
申请号：KR1020110049894
申请日：2011-05-26
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/166 , A61K31/16 , A61K31/06 , A61P21/00
Abstract: 본 발명은 AG490 화합물을 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물에 관한 것으로서, 보다 구체적으로 본 발명은 AG490 화합물을 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물에 관한 것이다. 본 발명에 따른 AG490 화합물은 염증성 사이토카인을 생성 및 분비하는 병인성 Th17 세포의 분화를 억제하는 효과가 우수하고, 비정상적으로 활성화된 면역세포의 기능을 억제하고 염증 반응을 제어하는 특성을 갖는 면역조절 T 세포(Treg)의 활성을 증진시키는 효과가 우수하면서도 p53 유전자의 발현을 촉진시키므로 각종 면역반응의 조절 이상으로 유발되는 자가면역질환, 염증성질환 및 이식거부질환과 같은 면역질환을 예방 또는 치료할 수 있는 약학적 조성물 또는 면역 억제제로 유용하게 사용할 수 있다.
-
公开(公告)号：KR1020130091044A
公开(公告)日：2013-08-16
申请号：KR1020120012268
申请日：2012-02-07
Applicant: 가톨릭대학교 산학협력단
IPC: A61K48/00 , A61K39/395
CPC classification number: A61K48/005 , A61K39/3955 , A61K2121/00
Abstract: PURPOSE: A composition for prevention and treatment of an immune disease including an expression or activity inhibitor of JunB is provided to be used in manufacture of a medicine for treating various immune diseases that are caused by an abnormal immune control when expression or activity of JunB is inhibited. CONSTITUTION: A composition for prevention and treatment of an immune disease comprises at least one selected from the group consisting of an antisense nucleotide complementarily binding to mRNA of gene JunB, a short interfering RNA, a short hairpin RNA, and an antibody with respect to JunB protein. The gene JunB is formed of polynucleotides of SEQ ID NO:1. The polynucleotides of the SEQ ID NO: 1 code a polypeptide of SEQ ID NO:2.
Abstract translation: 目的：提供一种用于预防和治疗JunB的表达或活性抑制剂的免疫疾病的组合物，用于制备用于治疗JunB的表达或活性时异常免疫控制引起的各种免疫疾病的药物 抑制。 构成：用于预防和治疗免疫疾病的组合物包含选自下组中的至少一种：与JunB基因互补结合的基因JunB的mRNA，短干扰RNA，短发夹RNA和针对JunB的抗体 蛋白。 基因JunB由SEQ ID NO：1的多核苷酸形成。 SEQ ID NO：1的多核苷酸编码SEQ ID NO：2的多肽。
-
125.发明授权
-
Patent Agency Ranking126.发明公开간엽줄기세포 및 면역조절 Ｔ 세포를 유효성분으로 포함하는 이식편대숙주질환 예방 또는 치료용 세포치료제 조성물 无效用于预防或治疗包含MESENCHYMAL STEM细胞和调节性T细胞的GRAFT-VERSUS-HOST疾病的细胞治疗组合物
公开(公告)号：KR1020120095022A
公开(公告)日：2012-08-28
申请号：KR1020110014398
申请日：2011-02-18
Applicant: 가톨릭대학교 산학협력단
CPC classification number: A61K35/28 , A61K31/21 , A61K35/17 , A61K39/001 , A61K2039/5158 , C12N5/0637 , C12N5/0667 , C12N2501/15 , C12N2501/51 , C12N2501/515 , A61K2300/00
Abstract: PURPOSE: A cell therapy composition for preventing or treating graft-versus-host diseases including immune-modulating T cells and mesenchymal stem cells is provided to control rejection against the host after transplanted marrow is engrafted, thereby reducing the generation of the graft-versus-host diseases. CONSTITUTION: A cell therapy composition for preventing or treating graft-versus-host diseases includes immune-modulating T cells and mesenchymal stem cells. The mesenchymal stem cell is a human derivative mesenchymal stem cell. The immune-modulating T cell is an immune-modulating T cell which is induced by retinal. The immune-modulated T cell is CD4+CD25+ immune-modulated T cell which is induced by processing retinal, anti-CD3, TGF-b, and anti-CD28 on the CD4+ T cell. The composition includes 1×10^4 cell/kg-1×10^8 cell/kg of the Cell Therapy Products.
Abstract translation: 目的：提供用于预防或治疗移植物抗宿主病，包括免疫调节性T细胞和间充质干细胞的细胞治疗组合物，用于在移植骨髓后控制对宿主的排斥反应，从而减少移植物抗宿主病的产生， 宿主病。 构成：用于预防或治疗移植物抗宿主病的细胞治疗组合物包括免疫调节T细胞和间充质干细胞。 间充质干细胞是人类衍生的间充质干细胞。 免疫调节性T细胞是由视网膜诱导的免疫调节性T细胞。 免疫调节的T细胞是通过在CD4 + T细胞上处理视网膜，抗CD3，TGF-b和抗CD28诱导的CD4 + CD25 +免疫调节的T细胞。 该组合物包括1×10 ^ 4细胞/ kg-1×10 ^ 8细胞/ kg的细胞治疗产品。
-
公开(公告)号：KR1020120026208A
公开(公告)日：2012-03-19
申请号：KR1020100088295
申请日：2010-09-09
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/015 , A61P35/00
Abstract: PURPOSE: A composition containing STA-21 for preventing or treating cancer or immune diseases is provided to suppress cytotoxic Th17 cell differentiation and to control inflammation. CONSTITUTION: A composition for preventing and treating cancer or immune diseases contains STA-21 compounds of chemical formula 1 or pharmacetuically acceptable salt thereof as an active ingredient. The STA-21 promotes or increases activation or amplification of regulatory T cells. A method for reducing or suppressing differentiation of undifferentiated T cells into Th17 cells in vitro comprises a step of treating STA-21 compounds or pharmaceutically acceptable salt thereof to the undifferentiated cells. A composition for anticancer or immunodepression contains STA-21 compounds or pharmaceutically acceptable salt thereof as an active ingredient.
Abstract translation: 目的：提供含有用于预防或治疗癌症或免疫疾病的STA-21的组合物，以抑制细胞毒性Th17细胞分化并控制炎症。 构成：用于预防和治疗癌症或免疫疾病的组合物含有化学式1的STA-21化合物或其药学上可接受的盐作为活性成分。 STA-21促进或增加调节性T细胞的活化或扩增。 未分化T细胞在体外分化为Th17细胞的方法包括将STA-21化合物或其药学上可接受的盐处理至未分化细胞的步骤。 用于抗癌或免疫抑制的组合物含有STA-21化合物或其药学上可接受的盐作为活性成分。
-
128.发明公开ＥＧＣＧ를 유효성분으로 함유하는 쇼그렌 증후군, 베체트 증후군, 강직성척추염 또는 루프스의 예방 또는 치료용 조성물 有权用于预防或治疗SJOGREN综合征，BEHCET综合征，包括作为活性成分的EGCG的神经系统性红斑狼疮或系统性红斑狼疮的组合物
公开(公告)号：KR1020110128542A
公开(公告)日：2011-11-30
申请号：KR1020100048052
申请日：2010-05-24
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/353 , A61K31/355 , A23L1/30
CPC classification number: A61K31/353 , A23L33/10 , A23V2002/00 , A23V2200/324 , A61K31/355
Abstract: PURPOSE: A pharmaceutical composition containing EGCG(epigallocatechin gallate) is provided to suppress differentiation of cytotoxic Th17 cells and to prevent or treat Sjogren syndrome, Behcet syndrome, or lupus. CONSTITUTION: A composition for preventing or treating Sjogren syndrome, Behcet syndrome, or lupus contains EGCG(epigallocatechin gallate) compound or salt thereof as an active ingredient. The EGCG suppresses or reduces differentiation of undifferentiated T cells into Th17 cells. A method for activating regulatory T cells comprises a step of treating the EGCG compounds or salt thereof to the T cells(Treg) in vitro. A functional food for treating or preventing Sjogren syndrome, Behcet syndrome, or lupus contains the EGCG compound or salt thereof as an active ingredient. A composition for suppressing immunity contains the EGCG compounds or salt thereof as an active ingredient.
Abstract translation: 目的：提供含有EGCG（表没食子儿茶素没食子酸酯）的药物组合物，以抑制细胞毒Th17细胞的分化，并预防或治疗干燥综合征，白塞综合征或狼疮。 构成：用于预防或治疗干燥综合征，白塞综合征或狼疮的组合物含有EGCG（表没食子儿茶素没食子酸酯）化合物或其盐作为活性成分。 EGCG抑制或减少未分化T细胞分化为Th17细胞。 用于激活调节性T细胞的方法包括在体外将T细胞（Treg）处理EGCG化合物或其盐的步骤。 用于治疗或预防干燥综合征，白塞综合征或狼疮的功能性食物含有EGCG化合物或其盐作为活性成分。 用于抑制免疫的组合物含有EGCG化合物或其盐作为活性成分。
-
公开(公告)号：KR1020110092237A
公开(公告)日：2011-08-17
申请号：KR1020110010999
申请日：2011-02-08
Applicant: 가톨릭대학교 산학협력단
IPC: A61K38/16 , A61K31/7105 , A61P29/00 , A61P37/00
CPC classification number: A61K38/16 , Y10S514/825 , Y10S514/857 , Y10S514/866 , Y10S514/885 , Y10S514/886 , Y10S514/894 , Y10S514/903 , Y10S514/925
Abstract: PURPOSE: A composition containing Grim19 for preventing or treating immune diseases is provided to suppress cytotoxic Th17 cell differentiation and to activate regulatory T cells. CONSTITUTION: A composition for preventing or treating immune diseases contains Grim19 protein as an active ingredient. The Grim19 protein has an amino acid sequence of sequence number 1. The immune diseases are autoimmune diseases, inflammatory diseases, and transplantation rejection diseases of cells, tissues, or organs. A method for activating regulatory T cells comprises a step of treating Grim 19 protein or an expression vector to the T cells. The expression vector contains a polynucleotide encoding Grim19 protein.
Abstract translation: 目的：提供含有用于预防或治疗免疫疾病的Grim19的组合物，以抑制细胞毒性Th17细胞分化并激活调节性T细胞。 构成：用于预防或治疗免疫疾病的组合物含有Grim19蛋白作为活性成分。 Grim19蛋白具有序列号1的氨基酸序列。免疫疾病是细胞，组织或器官的自身免疫疾病，炎性疾病和移植排斥疾病。 用于激活调节性T细胞的方法包括对T细胞处理Grim19蛋白或表达载体的步骤。 表达载体含有编码Grim19蛋白的多核苷酸。
-
130.发明公开
公开(公告)号：KR1020110049627A
公开(公告)日：2011-05-12
申请号：KR1020100025050
申请日：2010-03-22
Applicant: 에이치 엘 지노믹스(주) , 가톨릭대학교 산학협력단
Abstract: PURPOSE: A pharmaceutical composition containing Vitis vinifera seed extract is provided to prevent and treat gastrointestinal ulcer. CONSTITUTION: A pharmaceutical composition for preventing or treating gastrointestinal ulcer contains Vitis vinifera seed extract and pharmaceutically acceptable carrier. The extract of Vitis vinifera seeds contains 80-130 of procyanidolic value(PCV); 30% or less of (+)catechin and (-) epicatechin; and 95-105% of proanthocyanidin. A method for preparing the Vitis vinifera seed extract comprises: a step of extracting Vitis vinifera seed seeds in a mixture solvent of acetone and water and filtering; a step of distilling liquid and removing acetone; a step of saturating sodium chloride and filtering; a step of extracting the liquid with ethyl acetate and concentrating; and a step of adding chloroform and filtering to obtain precipitate.
Abstract translation: 目的：提供含有葡萄籽提取物的药物组合物，用于预防和治疗胃肠溃疡。 构成：用于预防或治疗胃肠溃疡的药物组合物含有葡萄种子提取物和药学上可接受的载体。 葡萄籽提取物含有原花青素含量（PCV）80-130; 30％以下（+）儿茶素和（ - ）表儿茶素; 和95-105％的原花色素。 一种葡萄种子提取物的制备方法，其特征在于：在丙酮和水的混合溶剂中提取葡萄种子种子并过滤; 蒸馏液并除去丙酮的步骤; 使氯化钠饱和并过滤的步骤; 用乙酸乙酯萃取液体并浓缩的步骤; 并加入氯仿和过滤以获得沉淀物的步骤。
-
-
-
-
-
-
-
-
-
Search Results
262
records
(took 0.039 seconds)
